The discussion of drugs in development continues, with specific focus on the treasure trove of data Intercept is producing for OCA and why combination therapy will probably be critical element in the long-term treatment strategy for NASH.
Stephen Harrison discusses the state of NASH Drug Development in 2022 with focus on the key steps on the pathway and how late-stage NASH drugs are progressing
Stephen Harrison leads a review of drug development and where we are in the NASH pipeline as Jörn Schattenberg, Louise Campbell and Roger Green lend their own perspectives and ask questions
On May 6 and 7, over 100 NAFLD stakeholders convened in Barcelona and online for the inaugural Innovations in NAFLD Care 2022 conference (#INCBCN.)
Co-chair Jeff Lazarus joins the Surfers (including co-chair Jörn Schattenberg) to review last week’s Innovations in NAFLD Care 2022 conference PLUS Roger Green interviews one of the events’ speakers, Human Edge CEO Dr. Marcus Ranney
Patient advocates Andrew Scott from the Global Liver Institute and Achim Kautz from Germany share their backgrounds, perspective, goals, and strategies with the Surfers.
Ian Rowe and Rachel Zayas join the Surfers to help Surfing the NASH Tsunami preview the 5th Global NASH Congress.
This conversation between Donna Cryer, Louise Campbell and Roger Green focuses largely on NASH patient care and digital health issues. Listen to learn why Roger Green believes the liver (and particularly Fatty Liver) might benefit more from digital therapeutics than any other organ system.
Naim Alkhouri joins Louise Campbell and Roger Green to discuss two of his recent publications, one estimating US prevalence based in NHANES data and the other looking at how the treatment choices a physician makes for Type 2 Diabetes can affect long-term NAFLD and NASH incidence.
This episode is Sponsored by Resoundant.
What are the practical benefits and challenges for clinicians wishing to deploy MRE (through MAST and/or Hepatogram along with PDFF) as an outpatient test in NASH Clinical Practice?
